Back to top
more

Crinetics Pharmaceuticals (CRNX)

(Delayed Data from NSDQ)

$43.83 USD

43.83
572,256

-0.37 (-0.84%)

Updated Jul 5, 2024 04:00 PM ET

After-Market: $43.90 +0.07 (0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 249)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Crinetics Pharmaceuticals, Inc. [CRNX]

Reports for Purchase

Showing records 1 - 20 ( 87 total )

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1

06/04/2024

Daily Note

Pages: 4

Atumelnant Wows at ENDO; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 2

05/23/2024

Daily Note

Pages: 3

Positive Initial Data From Atumelnant Phase 2 Study Suggests Another Winner for Crinetics; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 3

05/10/2024

Company Report

Pages: 5

Paltusotine NDA Submission On Track, Eyes On Phase 2 Results Of Atumelnant at ENDO

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 4

04/05/2024

Industry Report

Pages: 6

Long Overlooked, Graves? Disease Goes In Vogue With New Approaches

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 5

03/20/2024

Company Report

Pages: 5

Paltusotine Sets the New Standard in Acromegaly; We Raise Our Price Target to $60

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 6

03/19/2024

Daily Note

Pages: 3

Paltusotine Aces PATHFNDR-2 and Clears the Path to Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 7

03/13/2024

Daily Note

Pages: 4

With Positive Carcinoid Syndrome Data Confirmed, Paltusotine Looks to Phase 3; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 8

03/08/2024

Company Report

Pages: 5

Eyes on PATHFNDR-2 Readout This Month; Raise Price Target to $50

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 9

01/19/2024

Company Report

Pages: 39

Setting Expectations For PATHFNDR-2; A Comprehensive Slide Deck

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 75.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 10

12/19/2023

Company Report

Pages: 5

Paltusotine Comes Up Aces Again; Price Target Up to $42

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 11

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for CRNX 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 12

11/08/2023

Company Report

Pages: 5

3Q Update; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 13

09/14/2023

Daily Note

Pages: 5

Tens Across the Board for Paltusotine in PATHFNDR-1; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 14

09/11/2023

Daily Note

Pages: 4

Paltusotine Aces PATHFNDR-1; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 15

08/11/2023

Daily Note

Pages: 4

Top Takeaways from KOL Webinar on Acromegaly

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 16

08/09/2023

Company Report

Pages: 5

Enthusiasm For Paltusotine is Clear With Readout on Deck; Adjusting PT to $33 With Setback for CHI Program; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 17

06/20/2023

Daily Note

Pages: 6

Takeaways from our Conversation with Crinetics Pharmaceuticals and ENDO 2023; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 18

06/08/2023

Company Report

Pages: 43

Previewing PATHFNDR Readouts For Paltusotine; A Comprehensive Slide Deck

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 50.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 19

06/06/2023

Industry Report

Pages: 4

Emerging Ideas in Biopharma Call Series

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Crinetics Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 20

05/05/2023

Company Report

Pages: 5

Resizing for PATHFNDR-2 Bodes Well for Paltusotine; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party